Patent US4507303A successfully refreshed from Google Patents.
US4507303A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Succinimide derivatives, compositions and method of use
Assignee: Sumitomo Pharma Co Ltd
•
Filing: 1982-12-01
•
Granted: 1985-03-26
•
Expires: 2002-12-01
Abstract
Abstract Succinimide derivatives representable by the following formula: ##STR1## wherein X and Y are combined to form a group of the formula: ##STR2## (wherein A is an oxygen atom, a methylene group or an ethylene group and a full line accompanying a broken line ( ) is a single bond or a double bond) and Z is a hydrogen atom or, X and Z are combined to form a group of the formula: ##STR3## (wherein A and a full line are each as defined above) and Y is a hydrogen atom, R is a phenyl group, optionally substituted with halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy or trifluoromethyl, a 2-pyridyl group or a 2-pyrimidinyl group and n is an integer of 3 or 4, and pharmaceutically acceptable acid addition salts thereof, which are useful as antianxious substances.
Inventors
- 👤 Kikuo Ishizumi
- 👤 Fujio Antoku
- 👤 Yukio Asami
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 21:15
CPC Classifications
C; C07; C07D; C07D401/00; C07D401/02; C07D401/12; C07D209/00; C07D209/56; C07D209/58; C07D209/72; C07D209/76; C07D403/00; C07D403/02; C07D403/12
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
83 words
A succinimide derivative of the formula: ##STR21## wherein A is an oxygen atom, a methylene group or an ethylene group and a full line accompanying a broken line ( ) is a single bond or a double bond, R is a phenyl group, optionally substituted with halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy or trifluoromethyl, a 2-pyridyl group or a 2-pyrimidinyl group and n is an integer of 3 or 4, or a pharmaceutically acceptable acid addition salt thereof.
Claim 2
Dependent Claim
83 words
A succinimide derivative of the formula: ##STR21## wherein A is an oxygen atom, a methylene group or an ethylene group and a full line accompanying a broken line ( ) is a single bond or a double bond, R is a phenyl group, optionally substituted with halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy or trifluoromethyl, a 2-pyridyl group or a 2-pyrimidinyl group and n is an integer of 3 or 4, or a pharmaceutically acceptable acid addition salt thereof.
Claim 3
Dependent Claim
41 words
The succinimide derivative as claimed in claim 1, which is a compound of the formula: ##STR22## wherein A 1 is a methylene group or an ethylene group and the full line accompanying a broken line is as defined in claim 1.
Claim 4
Dependent Claim
19 words
The succinimide derivative as claimed in claim 1, which is N-[4-{4-(2-pyrimidinyl)-1-piperazinyl}butyl]bicyclo[2.2.1]heptane-2,3,di-exo-carboximide or a pharmaceutically acceptable acid addition salt thereof.
Claim 5
Dependent Claim
19 words
The succinimide derivative as claimed in claim 1, which is N-[4-{4-(2-pyrimidinyl)-1-piperazinyl}butyl]bicyclo[2.2.1]heptane-2,3-di-endo-carboximide or a pharmaceutically acceptable acid addition salt thereof.
Claim 6
Dependent Claim
19 words
The succinimide derivative as claimed in claim 1, which is N-[4-{4-(2-pyrimidinyl)-1-piperazinyl}butyl]bicyclo[2.2.2]octane-2,3-dicarboximide or a pharmaceutically acceptable acid addition salt thereof.
Claim 7
Dependent Claim
34 words
A pharmaceutical composition which comprises as an active ingredient a pharmaceutically effective amount of at least one of the compounds claimed in claim 1 and at least one pharmaceutically acceptable inert carrier or diluent.
Claim 8
Dependent Claim
30 words
A pharmaceutical composition which comprises as an active ingredient a pharmaceutically effective amount of the succinimide derivative of claim 3, and at least one pharmaceutically acceptable inert carrier or diluent.
Claim 9
Dependent Claim
21 words
A method for reducing anxiety, comprising: administering an effective anxiety reducing amount of the composition of claim 6 to a subject.
Claim 10
Dependent Claim
21 words
A method for reducing anxiety, comprising: administering an effective anxiety reducing amount of the composition of claim 7 to a subject.
References Cited (Backward Citations)
US2928846A
Cited
US3184456A
Cited
US3398151A
Cited
US3717634A
Cited
US3907801A
Cited
US3850922A
Cited
US3976776A
Cited
US4182763A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-03-25 | 1988-09-24 | 1989-03-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-03-25 | 1992-09-24 | 1993-03-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-03-25 | 1996-09-24 | 1997-03-26 | $7700.00 | Window Closed / Lapsed |